ORIC Pharmaceuticals, Inc. (ORIC)

ORIC Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-127.85	-100.7	-89.12	-78.72	-73.7
Depreciation & Amortization	1.11	1.03	0.97	0.9	0.97
Loss (Gain) From Sale of Assets	-	0.02	0.04	0	-
Asset Writedown & Restructuring Costs	-	-	-	-	19.84
Loss (Gain) From Sale of Investments	-8.1	-6.17	-1.04	1.35	0.3
Stock-Based Compensation	20.21	15.23	14.46	12.85	5.28
Change in Accounts Payable	1.83	3.28	-1.48	2.93	4.3
Change in Other Net Operating Assets	0.14	1.62	1.03	1.14	-2.26
Operating Cash Flow	-112.66	-85.69	-75.14	-59.54	-45.27
Capital Expenditures	-1.19	-0.85	-2.08	-0.94	-0.67
Investment in Securities	23.33	-42.55	-107.17	159.37	-215.49
Other Investing Activities	-	-	-	-	0.19
Investing Cash Flow	22.14	-43.4	-109.25	158.44	-215.96
Issuance of Common Stock	126.72	85.89	25.62	50.99	271.75
Other Financing Activities	-0.17	-0.23	-0.4	-1.85	-21.24
Financing Cash Flow	126.55	85.66	25.23	49.13	250.51
Net Cash Flow	36.02	-43.43	-159.17	148.03	-10.71
Free Cash Flow	-113.85	-86.54	-77.22	-60.48	-45.94
Free Cash Flow Per Share	-1.63	-1.68	-1.95	-1.59	-2.09
Levered Free Cash Flow	-67.1	-49.08	-42.02	-32.71	-23.87
Unlevered Free Cash Flow	-67.1	-49.08	-42.02	-32.71	-23.87
Change in Net Working Capital	-2.08	-4.75	1.14	-3.78	-1.39

Updated Feb 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q